A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors

Investigational New Drugs

Volumn 23, Issue 6, 2005, Pages 555-562

  Otterson, G A ^a   Lavelle, J ^a   Villalona Calero, M A ^a   Shah, M ^a   Wei, X ^b   Chan, K K ^a,b   Fischer, B ^a   Grever, M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cisplatin; Fenretinide; Paclitaxel; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FENRETINIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SYNCOPE; THYROID MEDULLARY CARCINOMA; TONGUE CANCER; UNCONSCIOUSNESS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FENRETINIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 31544461267     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1665-2     Document Type: Article

References (28)

1. Lippman SM, Kessler JF, Meyskens FL, Jr.: Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep 71(4): 391-105, 1987
2. Naik HR, Kalemkerian G, Pienta KJ: 4-Hydroxyphenylretinamide in the chemoprevention of cancer. Adv Pharmacol 33: 315-347, 1995
3. Delia D, et al.: N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53(24): 6036-6041, 1993
4. Mariotti A, et al.: N-(4-hydroxyphenyl)retinamide: A potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86(16): 1245-1247, 1994
5. Oridate N, et al.: Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention. J Cell Biochem Suppl 23: 80-86, 1995
6. Lotan R.: Retinoids and apoptosis: Implications for cancer chemoprevention and therapy [editorial; comment]. J Natl Cancer Inst 87(22): 1655-1657, 1995
7. Kalemkerian GP, et al.: Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines [see comments]. J Natl Cancer Inst 87(22): 1674-1680, 1995
8. Zou CP, et al.: Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4(5): 1345-1355, 1998
9. Sun SY, Yue P, Lotan R: Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 55(3): 403-410, 1999
10. Sun SY, et al.: Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59(10): 2493-2498, 1999
11. Maurer BJ, et al.: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines [see comments]. J Natl Cancer Inst 91(13): 1138-1146, 1999
12. Cobleigh MA, et al.: Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11(3): 474-477, 1993
13. Costa A, et al.: Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 25(5): 805-808, 1989
14. Liebmann JE, et al.: Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6(1): 25-31, 1994
15. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23(1 Suppl 1): 37-13, 1996
16. Kalemkerian GP, Ou X: Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 43(2): 145-150, 1999
17. Vaishampayan U, et al.: Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs, 23(2): 179-185, 2005
18. Puduvalli VK, et al.: Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21): 4282-4289, 2004
19. Therasse P, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comments]. J Natl Cancer Inst 92(3): 205-216, 2000
20. Doose DR, et al.: Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 32(12): 1089-1095, 1992
21. Formelli F, et al.: Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11(10): 2036-2042, 1993
22. Garaventa A, et al.: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9(6): 2032-2039, 2003
23. Hultin TA, et al.: Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice. Drug Metab Dispos 16(6): 783-788, 1988
24. Pitlick WH, et al.: Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65(3): 462-463, 1976
25. Conley B, et al.: Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18(2): 275-283, 2000
26. Singletary SE, et al.: Phase II clinical trial of N-(4-Hydroxyphenyl) retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 8(9): 2835-2842, 2002
27. Veronesi U, et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [In Process Citation]. J Natl Cancer Inst 91(21): 1847-1856, 1999
28. Gupta A, et al.: Effects of dietary N-(4-hydroxyphenyl)retinamide on N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fischer 344 rat. J Natl Cancer Inst 93(13): 990-998, 2001